Adaptimmune

Adaptimmune

Adaptimmune

Adaptimmune is a multinational, clinical-stage #biotech company focused on developing novel immunotherapies that can potentially transform cancer treatment
Type
B2c
Founded
2008
Raised
$42M
Follow us
Alexa global traffic share
Twitter followers
Latest funding
$42,000,000
Post-IPO equity - 2017
Team Size
50+
Employees
$42,000,000 Post-IPO equity
biospace

Adaptimmune Announces Closing Of 42 Million Registered Direct Offering